MicroBiome Therapeutics™ Reports Positive Top-Line Results From Clinical Trial Of Microbiome Modulator NM504 In Type 2 Diabetes - KFVS12 News & Weather Cape Girardeau, Carbondale, Poplar Bluff

MicroBiome Therapeutics™ Reports Positive Top-Line Results From Clinical Trial Of Microbiome Modulator NM504 In Type 2 Diabetes

  • HealthMore>>

  • FDA to propose e-cigarette regulations

    FDA to propose e-cigarette regulations

    © FDA© FDA
    The U.S. Food and Drug Administration is proposing long-awaited regulations governing the fast-growing electronic cigarette industry.
    The U.S. Food and Drug Administration is proposing long-awaited regulations governing the fast-growing electronic cigarette industry.
  • People seek out health info when famous person dies

    People seek out health info when famous person dies

    WEDNESDAY, April 23, 2014 (HealthDay News) -- The deaths of well-known people offer an opportunity to educate the general public about disease detection and prevention, a new study suggests. Researchers surveyed 1,400 American men and women after Apple co-founder Steve Jobs died of pancreatic cancer in 2011 and learned that more than one-third of them sought information about his cause of death or information about cancer in general soon after his death was reported. About 7 percent of th...
    WEDNESDAY, April 23, 2014 (HealthDay News) -- The deaths of well-known people offer an opportunity to educate the general public about disease detection and prevention, a new study suggests. Researchers surveyed 1,400 American men and women after Apple co-founder Steve Jobs died of pancreatic cancer in 2011 and learned that more than one-third of them sought information about his cause of death or information about cancer in general soon after his death was reported. About 7 percent of th...
  • 1 in 13 U.S. schoolkids takes psych meds

    1 in 13 U.S. schoolkids takes psych meds

    More than 7 percent of American schoolchildren are taking at least one medication for emotional or behavioral difficulties, a new government report shows.
    More than 7 percent of American schoolchildren are taking at least one medication for emotional or behavioral difficulties, a new government report shows.

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE MicroBiome Therapeutics LLC

--Statistically Significant Positive Results from First Double-Blind, Randomized Clinical Trial of a Microbiome Modulator for Diabetes--

--NM504 Significantly Improved Glucose Control in Patients with Prediabetes and Type 2 Diabetes--

BROOMFIELD, Colo., Feb. 18, 2014 /PRNewswire/ -- MicroBiome Therapeutics LLC, (MBT) today announced positive top-line results from the company's clinical trial of lead microbiome modulator NM504 in development for type 2 diabetes and prediabetes. NM504 is designed to improve glucose tolerance and other metabolic parameters in patients with diabetes by shifting the gastrointestinal (GI) microbiome. Studies have shown that type 2 diabetics typically have GI dysbiosis, or microbial imbalances, that may contribute to the metabolic dysfunction associated with the condition.

The double-blind, randomized, placebo-controlled trial assessed whether NM504 administered for four weeks could improve the glucose tolerance of subjects with prediabetes and untreated type 2 diabetes by modulating the GI microbiome. The study enrolled 42 subjects.

Top-line results show that twice-daily oral administration of NM504 reduced postprandial serum glucose levels and increased insulin sensitivity in these subjects. The results were statistically significant as measured by an oral glucose tolerance test. NM504 also decreased markers of chronic inflammation and blood lipids in treated subjects, and it decreased appetite as determined by a validated physician-administered scale. NM504 was well tolerated and patient compliance was excellent.

"This trial represents a milestone both for MBT and the emerging field of microbiome therapy," noted Steve Orndorff, CEO of Microbiome Therapeutics. "NM504 is the first therapeutic shown to directly modulate the GI microbiome in diabetics, and this study is among the first randomized, placebo-controlled trials of a microbiome-based therapy to achieve a statistically significant medical outcome. We look forward to reporting more detailed data on this study at upcoming scientific meetings."    

"The rising toll in morbidity, mortality and cost attributable to diabetes makes the need for novel therapeutic approaches urgent," said MBT Clinical Advisory Board member David D'Alessio, MD, Professor of Medicine at the University of Cincinnati College of Medicine. "Recent research suggests that the microbiome can be manipulated for therapeutic benefit, and modulators such as NM504 may offer an entirely new way to address diabetes. In this pilot study, NM504 significantly improved glucose tolerance in subjects with diabetes and prediabetes, and it was able to do so in the absence of any change in dietary habits. These promising data support additional trials to further assess the potential utility of NM504 in diabetes and prediabetes."

NM504 is also being studied in a placebo-controlled, double-blinded, proof of concept trial testing its utility in combination with metformin in type 2 diabetes patients with adverse GI effects. In a recently-published case study, NM504 demonstrated the potential to mitigate the GI side effects associated with metformin.

MBT is developing microbiome modulators that alter microbial populations and their environment in the GI tract to address serious health conditions. The company's microbiome modulators are designed to act on multiple factors, augmenting the growth of targeted desirable bacterial strains and discouraging the growth of others. NM504 is formulated to promote microbiome shifts that positively affect metabolism and weight.

About MicroBiome Therapeutics
MicroBiome Therapeutics LLC (MBT), is a clinical stage biotechnology company developing pharmaceutical and medical food products that aim to improve health status by interacting with and altering the human microbiome. MBT is developing evidence-based microbiome modulators to address serious health conditions. Lead product NM504 is being tested in clinical trials for the management of insulin sensitivity and blood glucose levels and as an adjunct to metformin in patients with prediabetes and type 2 diabetes. For more information, visit www.mbiome.com.

Contacts: 

Media:

Steve Orndorff 

Barbara Lindheim

CEO

BLL Partners, LLC

MicroBiome Therapeutics

(212) 584-2276

(303) 544-2104 

blindheim@bllbiopartners.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

310 Broadway
Cape Girardeau, MO 63701

FCC Public File
publicfile@kfvs12.com
573-335-1212
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and KFVS12. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.